EGFR and neoplasm: Adequate tumour samples were obtained from 93.0% (66/71) rebiopsy and 94.0% (126/134) initial biopsy patients for EGFR mutation analysis (p = 0.765), and from 100% (8/8) rebiopsy and 99.1% (122/123) initial biopsy patients for ALK rearrangements analysis (p = 1.000).